innovation

Advancing neurodegenerative disease research at AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders

Andrea_Puletto — Wed, 02 Apr 2025 08:53:07 +0000

Advancing neurodegenerative disease research at AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders

Alexander Klein, Global Medical Neurodegeneration

Andrea_Puletto Wed 02/04/2025 - 10:53

At the AD/PD Congress, one of the leading global events for advancing science in Alzheimer’s and Parkinson’s diseases, we are reaffirming our commitment to tackling the challenges of these devastating neurodegenerative diseases. The conference provides an invaluable platform to connect with the scientific community, fuel dialogues that spark innovation, and drive progress in understanding the underlying mechanisms of these complex conditions.

Neurodegenerative diseases like Alzheimer’s and Parkinson’s present an urgent, unmet medical need. These conditions profoundly affect millions of individuals and their families worldwide, often robbing them of independence and quality of life. We recognize that current solutions often fall short in providing comprehensive care, and we are dedicated to researching to bridge these gaps with innovative solutions. To develop solutions effectively, we must first uncover the mysteries behind their onset and progression.

��ֳ�’s Parkinson's research program includes investigating mechanisms to inhibit the propagation of alpha-synuclein – a process believed to underlie the spread of neurodegeneration. Alongside this, we are advancing research into innovative therapies for symptom control, recognizing the diverse needs of each patient throughout their disease trajectory, from early to advanced stages.

We firmly believe that the patient voice is essential in shaping meaningful research and therapies. By prioritizing patient-led initiatives and collaborating directly with those affected, we ensure that our work reflects their needs, experiences, and hopes for the future. The Patient Engagement and Care Progression Research (PECPR) initiative, established in 2021 is a collaborative effort to bring the patient community into the heart of early research and clinical development. The initiative strives to improve patient outcomes by working together on a patient-centered research model, embedding patient involvement throughout ��ֳ�’s Parkinson’s drug development portfolio, and fostering global collaboration to advance Parkinson’s research.

In Alzheimer's, we're hoping to find therapies that can slow the progression of the disease, and recent data from our development program is also on show at AD/PD. Alzheimer’s disease occurs when harmful plaques and tangles comprised of β-amyloid and tau protein build up in the brain, disrupting its function and leading to cognitive decline and dementia.

By progressing the science, working together and listening to the patient voice, we aim to move closer to a world where no family has to face the burden of neurodegenerative disease alone. To every scientist and researcher who joined us at AD/PD — thank you. Your dedication and ideas inspire hope and progress. Together, we are working towards a better future in neurodegenerative science, for patients now and in the future.

solutions

34 Likes

Innovating in neurology: ��ֳ�'s commitment shines at AAN 2025

Andrea_Puletto — Wed, 02 Apr 2025 08:31:25 +0000

Innovating in neurology: ��ֳ�'s commitment shines at AAN 2025

Donatello Crocetta, Global Rare Disease＆Rare Medical

Andrea_Puletto Wed 02/04/2025 - 10:31

As we prepare for the American Academy of Neurology (AAN) congress, we're excited to showcase ��ֳ�'s dedication to transforming care for individuals living with neurological conditions. The AAN annual meeting isn't just an event; it's a gathering of the brightest minds in neurology, where breakthroughs are shared, and challenges are tackled head-on.

A focus on valuable solutions

At ��ֳ�, our passion in neurology is deeply rooted in our history. We have always strived to push the boundaries and redefine what is possible in neurological care. From creating a meaningful impact for conditions like generalized Myasthenia Gravis (gMG) to developing solutions for rare epileptic syndromes such as Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), ��ֳ� has consistently led with innovation and compassion. Our research explores the effect of these conditions on quality of life, not just for patients but also for their families, paving the way for better disease management and, ultimately, better lives.

Showcasing innovation at AAN

Among the 24 abstracts accepted for the AAN congress, we are presenting new late-stage clinical trial findings that support the efficacy and safety of our therapies in epilepsy; insights from a new international patient registry for gMG; and findings that progress our understanding of the disease course of TK2d.

��ֳ� is proud to host its inaugural US Rare Disease Connect in Neurology (RDCN) Annual Summit at the 2025 American Academy of Neurology (AAN) Annual Meeting to provide a forum for needs-driven medical education for the generalized myasthenia gravis community (gMG). This event is being held exclusively for healthcare providers who are involved in patient care. RDCN is an ongoing global learning program connecting a community of experts committed to delivering excellence for people living with gMG. The RDCN network is expanding to the US, specifically with the goal to foster collaboration for comprehensive gMG care.

Our commitment to science and care

First and foremost, ��ֳ�’s presence at AAN reflects our unwavering commitment to collaboration with the scientific, medical, and patient communities. We believe that engaging directly with those who live with these conditions, their caregivers, and healthcare providers allows us to tailor our strategies and focus on what truly matters.

Our commitment to collaboration and leveraging real-world insights is central to our approach as we strive to create a future where every person with a neurological condition can achieve optimized care and management. Together, we can drive change and shape a brighter future in the field of neurology, ensuring that our efforts translate into meaningful improvements for those who rely on our innovations.

solutions

innovation epilepsy neurology

27 Likes

Collaboration and innovation drives RealiseD Project to Change the Paradigm for Clinical Trials in Rare and Ultra-Rare Diseases

Andrea_Puletto — Fri, 28 Feb 2025 12:31:57 +0000

Collaboration and innovation drives RealiseD Project to Change the Paradigm for Clinical Trials in Rare and Ultra-Rare Diseases

Marc Vandemeulebroecke, Biometrics & Data Science

Andrea_Puletto Fri 28/02/2025 - 13:31

Imagine a world where every rare disease, no matter how uncommon, gets its moment in the spotlight of scientific innovation. Where the challenges of small patient populations and varied symptoms don't hinder progress but inspire a new approach to clinical studies. This is the mission at the heart of RealiseD, and ��ֳ� are proud to be part of this project which is funded by the Innovative Health Initiative (IHI) and will run until 2029.

With millions of people worldwide living with a rare disease, and many of these conditions being ultra-rare, the need for new treatments has never been more urgent. Yet, the path to developing these treatments is fraught with obstacles, from enrolling participants in clinical studies to navigating fragmented regulatory frameworks. That's where RealiseD steps in, with the aim of transforming the paradigm of clinical studies for rare and ultra-rare diseases.

But how, you might ask, can such an ambitious goal be achieved? The answer lies in collaboration and innovation. RealiseD is not just another research project; it's a comprehensive, collaborative effort to overhaul how clinical studies are conducted for the rarest of diseases. By bringing together experts from every corner of the healthcare ecosystem - academia, regulatory bodies, clinical research institutes and hospitals, patient organisations, and pharmaceutical companies – RealiseD is working to craft new gold standards for clinical trials in rare and ultra-rare diseases.

So, what can we take away from the ambitious mission of RealiseD? It's a reminder that in the face of daunting challenges, collaboration and innovation can light the way forward. It's a call to action for all of us in the healthcare industry to support and participate in efforts that push the boundaries of what's possible. And most importantly, it's a beacon of hope for the millions of people living with rare diseases, a promise that they are not forgotten and that the future holds the promise of new treatments.

The journey of RealiseD is just beginning, but its vision is crystal clear: a world where every rare disease is recognized, researched, and treated. ��ֳ� is proud to stand together in support of this noble mission, because we think that the impact of RealiseD will resonate for generations to come.

To stay updated on the progress of RealiseD and learn more you can visit their new website by clicking here.

innovation

innovation clinical research clinical trials

Comment:

Posted by Andrea Wilkinson , 28 February 2025

So proud to hear of your contribution to this important global initiative to drive changes in EU that we can all learn from! More, More, More!!

59 Likes

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

Andrea_Puletto — Thu, 09 Jan 2025 13:38:36 +0000

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

Dan Lightwood, Antibody Discovery and Optimisation

Andrea_Puletto Thu 09/01/2025 - 14:38

At ��ֳ�, our commitment to innovation is driven by one clear objective – to transform the lives of people living with severe diseases. Each partnership we pursue is carefully chosen to not only align with this mission but to amplify it. That's why we are thrilled to announce a groundbreaking collaboration with Ailux Biologics, a division of XtalPi, to propel biologics research into new territory.

This strategic partnership highlights ��ֳ�'s ongoing dedication to addressing unmet medical needs, harnessing cutting-edge technologies, and shaping a future where healthcare solutions are developed faster, smarter, and more effectively.

A Powerful Alliance for Scientific Innovation

Through our partnership with Ailux Biologics, we’ve licensed XtalFold™, an AI-powered biologics platform designed to provide rapid and accurate insights into antibody and antigen structures. By integrating this sophisticated technology into our biologics discovery and optimization workflows, we’re equipping our teams with enhanced capabilities to engineer high-quality therapeutic candidates more efficiently. We believe XtalFold™ has the potential to enhance ��ֳ�’s ability to rapidly and efficiently discover therapeutic antibody candidates and ultimately deliver new medicines to patients.

XtalFold™ sets itself apart by leveraging sequence information alone to predict biomolecular interactions, including the crucial antibody-antigen interface. This streamlined, sequence-driven approach offers exceptional precision, even in complex regions that were challenging to model in the past.

Addressing Unmet Needs Through Technology

With around 70% of immune and central nervous system diseases still classified as having unmet medical needs, accelerating the discovery of effective therapies is critical. XtalFold will allow us to leverage structural insights into the entire antibody discovery and optimisation workflow; allowing us to be more efficient in how we select and engineer antibodies with suitable drug-like properties.

Coupled with ��ֳ�’s robust in-house antibody discovery platforms, this collaboration establishes a dynamic synergy between human expertise and computational power. It’s a blend of innovation and experience that further strengthens our ability to bring meaningful solutions to patients around the world.

Anticipating the Path Ahead

This isn’t just a collaboration to benefit the present; it’s a strategic move that looks towards the future of biologics development. ��ֳ� and Ailux Biologics will continue to explore the full potential of AI in discovery processes, aiming to deliver milestones that redefine therapeutic solutions. By adopting state-of-the-art platforms, we expect to not only accelerate drug discovery but foster an environment where innovation thrives.

We’re proud of what this partnership signals not just for ��ֳ� but for patients around the globe. Together with Ailux Biologics, we will continue to challenge the boundaries of science, and work to open doors to treatments that were once unimaginable. This is only the beginning, and as we move forward, our vision remains unwavering – transforming lives, one discovery at a time.

innovation

innovation Our Science innovation medicines initiative

Comment:

Posted by Cecilia, 30 January 2025

Amazing news

188 Likes

What does the future look like for rare genetic epilepsies?

Andrea_Puletto — Fri, 06 Dec 2024 10:21:24 +0000

What does the future look like for rare genetic epilepsies?

Christian Wolff, Epilepsy Discovery Research

Andrea_Puletto Fri 06/12/2024 - 11:21

Research into rare genetic epilepsies is advancing rapidly, with multiple promising clinical developments that are underway. Across the industry, considerable efforts are being made to better care for people living with rare or treatment-resistant epilepsies through innovative science. At ��ֳ�, this means building a comprehensive understanding of the patient needs and the underlying causes of epilepsies, and seeking new ways to modify disease processes to improve outcomes.

Understanding the underlying disease mechanisms

Driving research into rare and treatment-resistant epilepsies requires us to combine our deep heritage in epilepsy with the latest technological innovations. By better understanding the molecular signatures and pathways that form the root causes of these complex diseases, it is opening up opportunities to target the underlying mechanisms that cause epilepsies.

KCNT1-related epilepsies are a group of rare epilepsies caused by a variation in the KCNT1 gene and include epilepsy of infancy with migrating focal seizures (EIMFS) and sleep-related hypermotor epilepsy (SHE). Most children have severe developmental and intellectual disability, and their seizures are difficult to control. ��ֳ� is collaborating with Praxis Precision Medicines, focusing on potential treatments for KCNT1-related epilepsies. This partnership aims to enhance understanding of the underlying causes of epilepsy, with a focus on exploring potential disease-modifying treatments.

It’s all part of our focus on disease modification, acting at the root cause of a disease rather than just addressing individual symptoms. By carefully observing the whole spectrum of symptoms and understanding of how epilepsies progress, coupled with research into the disease pathobiology, we hope to identify suitable targets for disease modification.

Beyond seizure control

The ultimate goal of our research is to find treatment approaches for people with rare genetic epilepsies who often struggle to find effective therapies and as a result, do not experience freedom from their persistent seizures. However, disease impact goes well beyond the symptomatic control of seizures and to make a meaningful impact on people’s lives we need to think more holistically about epilepsies.

For many people living with epilepsies, seizures are not always the primary or most impactful symptom they face in everyday life. Cognitive impairments, developmental delays, psychiatric conditions, and detrimental impacts on quality of life frequently accompany rare epilepsies yet are often underdiagnosed or inadequately treated. It’s essential that we consider these non-seizure outcomes associated with epilepsy as we seek to discover new solutions that look to improve quality of life holistically.

Several reports presented during this year’s American Epilepsy Society Congress (AES) focused on the relationship between sleep and epilepsy. A retrospective observational analysis found sleep apnea comorbidity is an important and potentially actionable factor associated with increased mortality in children and young adults with severe epilepsy. Traditionally sleep is assessed in a clinical setting using an elaborate electrical signal setup (EEG, ECG, EMG, EOG) * and respiration measurement. One study presented at AES found that sleep can be reliably assessed from a behind-the-ear EEG montage in an automated way in both healthy subjects and patients with Dravet Syndrome. The ability to assess sleep in a non-intrusive way has great potential to detect sleep-related co-morbidities associated with Dravet syndrome.

By better understanding the holistic challenges that the community faces we can drive advancements in how rare epilepsies are treated, with the full perspective of the patient and their family in mind.

A glimpse into the future

As we look to the future, it’s vital that we continue to raise awareness of rare epilepsies, partly due to the vast number of patients undiagnosed, but also to create a more supportive environment for all those living with these debilitating conditions.

The future of epilepsy research, particularly for rare genetic epilepsies, is promising. By focusing on new modalities, developing novel disease-modifying treatments, addressing comorbidities, and leveraging advanced technologies, we hope to find a way to not only control seizures but also improve overall quality of life for those living with epilepsies and their families. As our understanding of the epilepsy spectrum grows, so does the potential to explore new approaches that could change the course of rare epilepsies.

For more information about epilepsy, visit Epilepsy & Rare Syndromes at ��ֳ�.

* EEG (Electroencephalogram) measures electrical activity in the brain. ECG (Electrocardiogram) monitors heart rhythms and electrical activity. EMG (Electromyography) assesses muscle response. EOG (Electrooculography) tracks eye movements.

innovation

innovation Our Science Rare Disease

Comment:

Posted by Sarah Drislane, 6 December 2024

The KCNT1 Epilepsy Foundation is grateful for your continued work in understanding and developing treatments for KCNT1 -related disorders and other DEEs!

152 Likes

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Andrea_Puletto — Thu, 28 Nov 2024 08:53:01 +0000

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Veronique Toully, Sustainability, Corporate Affairs and Risks

Andrea_Puletto Thu 28/11/2024 - 09:53

Today, I am proud to announce that our new carbon emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi), a significant achievement that underscores our commitment to sustainable impact and our dedication to reducing our environmental footprint.

Specifically, our validated net-zero targets aim to reduce absolute scope 1, 2 and 3 greenhouse gas (GHG) emissions by 90% by 2045 (from our 2019 baseline), ensuring we are aligned with the latest climate science to meet the goals of the Paris Agreement and achieving net-zero before 2050.

This is an important step in a collection of actions we are taking to minimise our environmental footprint. We have started and will continue to embed green aspects and considerations from the very start of the creation of each of our medicines. And we are working closely with our suppliers to set and validate science-based targets for carbon emissions, supporting their shift towards a low-carbon economy.

At ��ֳ� we understand the intrinsic link between the health of people and the planet and believe that the pharmaceutical industry has a critical role to play. Healthcare systems have a large carbon footprint, accounting for an estimated 4.4% of global greenhouse gas emissions, and of those about 1/3 comes from medicines.

We are committed to demonstrating that business success and environmental stewardship are not mutually exclusive but rather mutually reinforcing. Setting science-based targets ensures our growth is sustainable by reducing costs, boosting investor confidence and enhancing our competitiveness and innovation. Sustainability is at the core of our operations, driving us to positively impact society and secure ��ֳ�'s long-term success.

This validation by the SBTi is the testament to the collective work and achievements in our environmental sustainability journey so far. It represents a pivotal moment, elevating our commitment towards a more sustainable future. Together, with the support of our colleagues, partners and stakeholders, we can achieve our vision of creating a healthier, more sustainable world.

“Climate change is one of the biggest challenges facing our planet today, causing devastating impacts such as extreme weather events, sea level rise, and loss of biodiversity. Achieving net-zero emissions is crucial in mitigating the climate crisis. We firmly believe that it is our responsibility to lead by example and take concrete steps towards a sustainable and resilient future. By setting ambitious, science-based targets, we aim to significantly reduce our carbon footprint and contribute to global efforts to mitigate the climate crisis.” Our CEO, Jean-Christophe Tellier, said. 

We invite you to join us on our journey toward a sustainable future. Stay connected and learn more about our initiatives by following me and ��ֳ� on LinkedIn and visiting our website at Reducing emissions | ��ֳ�.

about ucb

innovation sustainability our company

222 Likes

��ֳ� Belgium: A global hub of healthcare innovation

Andrea_Puletto — Wed, 20 Nov 2024 14:22:27 +0000

��ֳ� Belgium: A global hub of healthcare innovation

Jiri Keirsse, Public Private Partnerships & Innovation Strategy

Andrea_Puletto Wed 20/11/2024 - 15:22

Recognized by the European Innovation scoreboard, Belgium has positioned itself as a powerhouse in healthcare and pharmaceutical innovation, with a unique blend of academic rigor and industry expertise driving its success. This thriving ecosystem is characterized by strong collaboration between leading research institutions and pharmaceutical companies, setting Belgium apart on a global level. The partnership between ��ֳ� and KU Leuven, a renowned research institution, is a prime example of the country's collaborative spirit. With the potential to span early discovery to clinical proof of concept we are working to advance healthcare innovation, addressing unmet patient needs, and solidifying Belgium’s influence in the global healthcare landscape.

Belgium’s academic landscape is home to institutions like KU Leuven, which are not only centers of education but international communities where innovative research forms the basis of all their academic programs – they act as a catalyst and connector for innovation and scientific discovery. Like ��ֳ�, KU Leuven is at the forefront of cutting-edge research. They play a pivotal role in translating academic insights into practical healthcare applications with a keen focus on moving from ‘science to business’. That makes them a great partner for ��ֳ�; from unlocking the secrets of chemicals, cultivating the promises of pharmaceuticals and expanding into biologics, peptides and gene therapy, we at ��ֳ� are on a mission to continuously innovate. We also recognize that we cannot solve the world’s healthcare challenges alone, and so we know the value gained from collaboration across disciplines, geographies and stakeholders. Innovation has no boundaries, and real breakthroughs will result from the use of new technologies and trust-based collaboration and partnerships.

At the core of Belgium’s healthcare success is its collaborative ecosystem. The partnership between ��ֳ� and KU Leuven exemplifies how academia and industry are incentivized to work hand in hand to push the boundaries of knowledge and innovative science. The culture of collaboration is stimulated by open conversations, translating from the world of academia to drug development. Building a connection based on similar motivations develops an organic relationship between the two parties, and in turn creates the best environment for collaboration and partnerships.

The healthcare innovations born from Belgium's collaborative efforts have far-reaching impacts beyond its borders. Developments made in Belgium are being adopted worldwide, driving improvements in patient outcomes and setting new standards in the pharmaceutical industry. As the healthcare landscape continues to evolve, Belgium remains well-positioned to spearhead change in innovation. The future promises even stronger academic-industry collaborations, with emerging trends pushing the boundaries of scientific discovery. Belgium’s long-term vision as a hub of healthcare innovation is anchored in its commitment to fostering partnerships that fuel ongoing advancements. Through this sustained collaboration, Belgium will continue to play a vital role in shaping the future of global healthcare.

Belgium’s healthcare innovation ecosystem, driven by collaborations between ��ֳ� and KU Leuven, is a powerful force in the global pharmaceutical industry. The country’s continued commitment to partnership and innovation ensures its influence will only grow, leading to new breakthroughs and closing the gap of unmet needs globally.

We recently spoke with Bart Geers, an Investment Manager from KU Leuven, Research & Development about innovation and the need for collaboration and partnerships across academia and the pharmaceutical industry. Watch the video to learn more.

innovation

Science innovation our company

202 Likes

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Andrea_Puletto — Thu, 26 Sep 2024 12:26:46 +0000

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Snauwaert Adriaan, Immunology Global Communication

Andrea_Puletto Thu 26/09/2024 - 14:26

The American Society for Bone and Mineral Research (ASBMR) Annual Meeting is the largest and most comprehensive global congress dedicated to bone, mineral, and musculoskeletal health. Each year, thousands of leading experts, researchers, and clinicians from around the world gather to exchange knowledge and present the latest breakthroughs in disease management, treatment strategies, and scientific innovation. The 2024 meeting promises to continue this tradition of excellence, offering a unique platform for collaboration and discovery in the ever-evolving field of bone health.

This year, ��ֳ� and Amgen will unveil crucial new data that demonstrate significant advancements in reducing fracture risk and improving bone strength, particularly for patients at high risk of osteoporosis-related fractures. These findings will emphasize the value of new therapeutic approaches in comparison to existing treatments, highlighting their potential to transform osteoporosis care and improve long-term outcomes for patients.

At ��ֳ�, we remain dedicated to advancing research and ensuring patients have access to transformative treatments for osteoporosis. Earlier this year, we caught up with experts to discuss the urgent need to address bone health in aging populations and innovation in osteoporosis treatments. These conversations continue at ASBMR 2024, where we look forward to sharing groundbreaking data and collaborating with the global community to drive progress in bone disease management. Watch the video below!

Complementing this is our Fragility Fracture in Focus podcast series which explores how the P4 Health Spectrum (predictive, preventive, personalized, and participatory) – an increasingly recognized cornerstone of proactive modern medicine – looks to shift focus away from disease to the promotion of a state of wellness. Listen NOW to the Fragility Fractures in Focus podcast to find out more! (For healthcare professionals only).

Stay connected for updates throughout the congress, as we continue to push the boundaries of bone health research and patient care.

about ucb

innovation Immunology science

136 Likes

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach

Andrea_Puletto — Wed, 18 Sep 2024 09:12:23 +0000

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach

By Julie Tordo, Preclinical Gene Therapy

Andrea_Puletto Wed 18/09/2024 - 11:12

At ��ֳ�, we recognize that we cannot solve the world’s healthcare challenges alone, but that breakthroughs will result from the use of new technologies as well as open collaboration and partnerships. In fact, we believe that collaboration serves as a catalyst for advancement in science discovery. That is why we work hard to find great partners, because we know that the more, we collaborate, the more we can innovate.

The power of collaborations in fostering innovation cannot be understated. It’s about enabling diverse expertise to converge and tackle complex challenges from multiple angles. When researchers, academics, clinicians, and technology experts join forces they can work with agility, share insights, and leverage unique resources and experiences, all of which can expedite the journey from concept to innovation.

While vital for innovation, collaborations often come with their own set of challenges. Differences in culture, priorities and ways of working can create friction, leading to misunderstandings or misaligned expectations. Building trust is essential to navigate these complexities. It requires open communication and a willingness to empathize with one another’s perspectives. By fostering an environment where both parties feel valued and heard, we can collaboratively address these hurdles, paving the way for more successful partnerships.

I believe that trust is something we have established with KU Leuven, a world leading university and partner to ��ֳ�. At the heart of this partnership is a shared commitment to transforming cutting-edge scientific discoveries into therapeutic solutions. The collaboration brings together complementary skills and expertise provided by each partner, combining the theoretical, creative and experimental expertise of academia with the strategic and operational capabilities of pharma. The strength of the ��ֳ�-KU Leuven partnership is built on a foundation of trust and shared objectives, essential for nurturing an environment where innovative ideas can thrive. Our collaboration with KU Leuven, in the field of gene therapy, exemplifies how partnerships can drive scientific thinking. to accelerate progress towards new innovations.

Find out more about our passion for innovation here.

innovation

innovation innovation medicines initiative discovery

131 Likes

Advancing Our Gene Therapy Journey

Vandenbruaene Nathalie — Fri, 12 Jul 2024 06:49:46 +0000

Advancing Our Gene Therapy Journey

Christophe Dumont, Genesis Project

Vandenbruaene … Fri 12/07/2024 - 08:49

I am thrilled to share the latest progress on our groundbreaking gene therapy facility in Braine-l'Alleud, Wallonia, Belgium. The exterior of the facility is now complete, and we are currently moving forward with the “Fit Out” activities. The first equipment is delivered and already in place. This marks a significant milestone in our journey towards revolutionizing disease treatment through advanced gene therapy.

Why is this project important? For ��ֳ�, it means opening new opportunities to discover and develop cures for the people we serve. For me, it's deeply personal. People living with severe diseases are at the heart of everything we do, and every morning, I’m motivated by the thought that this facility could one day help my loved ones.

Beyond the personal and corporate impact, this state-of-the-art facility, representing a substantial investment in Belgium, is designed to be both innovative and environmentally sustainable. It will significantly enhance our development and manufacturing capabilities, reinforcing our existing teams in Braine-l’Alleud (Belgium), Leuven (Belgium), Boston (USA), and Durham (UK).

Our new facility will allow us to have complete ownership of our chemistry, manufacturing, and controls (CMC) capabilities. This will enable us to be more agile in responding to new trends and opportunities, and more scalable to meet the unmet needs of patients. The efficient clinical manufacturing capability will ensure we maintain high standards of speed, scalability, and quality as we bring our gene therapy research projects to patients.

Building Gene Therapy Skills

In addition to the physical construction of the facility, we are also committed to developing our skills and expertise in gene therapy and more largely bio-related fields. This field offers a wealth of opportunities for both current employees and new hires. We are excited to announce that the novel facility will create over 100 new, highly skilled jobs. We are actively seeking talented, inspired, and passionate individuals who are eager to join us in improving lives through innovative therapies.

If you have a passion for pushing the boundaries of what’s possible and making a real difference in patients' lives, we invite you to join our dynamic team. Exciting positions and unique opportunities await you at our cutting-edge facility.

Join Us on This Exciting Journey

The completion of this facility will expand ��ֳ�'s innovation footprint, which includes sites in Belgium, Japan, Switzerland, Germany, the US, and the UK. It will support our ambition for carbon neutrality by implementing the latest technologies and achieving BREEAM (Building Research Establishment Environmental Assessment Method certification), aiming to drastically reduce both resource consumption and waste production.

I look forward to the exciting advancements and innovations this new facility will bring. Together, we can transform the future of disease treatment and make a lasting impact on patients' lives. For more details, please visit our career page.

Join our team

about ucb

Gene Therapy innovation Braine-l'Alleud

385 Likes

innovation

Advancing neurodegenerative disease research at AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders

Leave a Comment

Innovating in neurology: ��ֳ�'s commitment shines at AAN 2025

A focus on valuable solutions

Showcasing innovation at AAN

Our commitment to science and care

Leave a Comment

Collaboration and innovation drives RealiseD Project to Change the Paradigm for Clinical Trials in Rare and Ultra-Rare Diseases

Leave a Comment

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

A Powerful Alliance for Scientific Innovation

Addressing Unmet Needs Through Technology

Anticipating the Path Ahead

Leave a Comment

What does the future look like for rare genetic epilepsies?

Understanding the underlying disease mechanisms

Beyond seizure control

A glimpse into the future

Leave a Comment

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Leave a Comment

��ֳ� Belgium: A global hub of healthcare innovation

Leave a Comment

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Leave a Comment

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach

Leave a Comment

Advancing Our Gene Therapy Journey

Building Gene Therapy Skills

Join Us on This Exciting Journey

Join our team

Leave a Comment

innovation

Advancing neurodegenerative disease research at AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders

Leave a Comment

Innovating in neurology: ������ֳ�'s commitment shines at AAN 2025

A focus on valuable solutions

Showcasing innovation at AAN

Our commitment to science and care

Leave a Comment

Collaboration and innovation drives RealiseD Project to Change the Paradigm for Clinical Trials in Rare and Ultra-Rare Diseases

Leave a Comment

������ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

A Powerful Alliance for Scientific Innovation

Addressing Unmet Needs Through Technology

Anticipating the Path Ahead

Leave a Comment

What does the future look like for rare genetic epilepsies?

Understanding the underlying disease mechanisms

Beyond seizure control

A glimpse into the future

Leave a Comment

������ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Leave a Comment

������ֳ� Belgium: A global hub of healthcare innovation

Leave a Comment

ASBMR Annual Meeting 2024 overview: prioritizing patient-centered care

Leave a Comment

Healthcare Innovation: ������ֳ� and KU Leuven’s Collaborative Approach

Leave a Comment

Advancing Our Gene Therapy Journey

Building Gene Therapy Skills

Join Us on This Exciting Journey

Join our team

Leave a Comment

Innovating in neurology: ��ֳ�'s commitment shines at AAN 2025

��ֳ� and Ailux Biologics Join Forces to Transform Biologics Research

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

��ֳ� Belgium: A global hub of healthcare innovation

Healthcare Innovation: ��ֳ� and KU Leuven’s Collaborative Approach